Myriad Genetics Blog Myriad Genetics Blog > Myriad Is Named to Forbes List of 100 Best Small Companies in America for Third Consecutive Year Myriad Is Named to Forbes List of 100 Best Small Companies in America for Third Consecutive Year October 15, 2014 Corporate We are honored by the ongoing recognition of Forbes Magazine for the outstanding business growth that our employees have achieved as we continue to drive superior value for our customers and our shareholders. This year Myriad moved up 33 spots in the Forbes ranking to number 16. The ranking reflects Myriad’s outstanding business performance. In FY2014 our revenues were a record $778 million, an increase of 27 percent over the prior year, and the Company’s five-year Compound Annual Growth Rate (CAGR) was approximately 17 percent. Importantly, we are well positioned to continue to deliver long-term value for our shareholders and address the diagnostic needs of today’s healthcare system. We have invested $200 million in R&D since 2011, and today have an industry-leading pipeline of new molecular diagnostic and companion diagnostic tests. We’re also focused on expanding internationally and bringing our life-saving products to more patients worldwide. Forbes 2014 list of the 100 Best Small Companies in America recognizes remarkable sales and earnings growth among public companies with annual revenues between $5 million and $1 billion and a stock price no lower than $5 a share. Rankings are based on earnings growth, sales growth and return on equity in the past 12 months and over five years, and on the company’s stock performance relative to its peer group. Read the Forbes article.